Alzheimer's disease (AD) is the leading cause of dementia, accounting for 60–70% of all
cases [Hebert et al., 2003, 1]. The need for effective therapies for AD is great. Current …

Background The order and magnitude of pathologic processes in Alzheimer's disease are
not well understood, partly because the disease develops over many years. Autosomal …

Vascular contributions to dementia and Alzheimer’s disease are increasingly recognized 1 ,
2 , 3 , 4 , 5 – 6 . Recent studies have suggested that breakdown of the blood–brain barrier (…

Vascular contributions to cognitive impairment are increasingly recognized 1 , 2 , 3 , 4 – 5 as
shown by neuropathological 6 , 7 , neuroimaging 4 , 8 , 9 , 10 – 11 , and cerebrospinal fluid …

The pathognomonic plaques of Alzheimer’s disease are composed primarily of the 39- to 43-aa
β-amyloid (Aβ) peptide. Crosslinking of Aβ peptides by tissue transglutaminase (tTg) …

Major imaging biomarkers of Alzheimer’s disease include amyloid deposition [imaged with [
11 C]Pittsburgh compound B (PiB) PET], altered glucose metabolism (imaged with [ 18 F]…

Dominantly inherited Alzheimer’s disease (DIAD) causes predictable biological changes
decades before the onset of clinical symptoms, enabling testing of interventions in the …

Parkinson disease (PD) is a neurodegenerative disorder characterized by motor and non-motor
symptoms which relentlessly and progressively lead to substantial disability and …

Amyloid-β (Aβ) is ubiquitous in the central nervous system (CNS), but pathologic accumulation
of Aβ results in four distinct neurologic disorders that affect middle-aged and elderly adults…

Alzheimer’s disease (AD) is characterized by two molecular pathologies: cerebral β-amyloidosis
in the form of β-amyloid (Aβ) plaques and tauopathy in the form of neurofibrillary tangles…